Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 3;44(12):116593.
doi: 10.1016/j.celrep.2025.116593. Online ahead of print.

Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV

Affiliations
Free article

Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV

Ahlam N Qerqez et al. Cell Rep. .
Free article

Abstract

Antibodies binding cell-surface antigens to activate cellular immunity are an important mechanism of anti-viral protection, yet antibodies targeting cells infected by human cytomegalovirus (HCMV) exhibit limited efficacy. This is due to HCMV immune evasion mechanisms, including viral receptors (vFcγRs) that bind human immunoglobulin G Fc domains to inhibit host Fcγ receptor activation and impair Fc-mediated immune functions. Here, we biochemically characterize two conserved vFcγRs, gp34 and gp68, and map their Fc binding sites. We then engineer Fc variants to retain binding to host Fc receptors CD16A and FcRn but exhibit markedly reduced gp34/gp68 interactions. Antibodies targeting the gB fusogen with engineered Fc domains are not internalized by infected cells, mediate enhanced immune cell activation, and limit viral spread in HCMV-infected fibroblasts more effectively than antibodies with wild-type Fc. This work demonstrates a strategy to enhance therapeutic antibody control of HCMV infections and other herpesvirus infections with similar immune-evasion mechanisms.

Keywords: CP: immunology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.N.Q., A.G.L., S.P., and J.A.M. are inventors on WO2023108117A2 (“Engineered Fc Domains and Engineered HCMV Viral Fc Receptors”). P.K. was funded by Biotest AG, who produces Cytotect (2022–2024), and serves as a consultant for Oak Hill Bio. R.J.S. has been a paid consultant for Vaccitech and Moderna on HCMV vaccines. J.S.M. and J.A.M. received funding from Dynavax to evaluate stabilized HCMV gB immunogens. These activities had no impact on this study.

LinkOut - more resources